Brought to you by 
Series B brings in CHF23.7mm for NovaShunt AG
23 Apr 2015
Executive Summary
NovaShunt AG (implantable pumps for fluid management) has raised CHF23.7mm ($25.6mm) in a Series B financing of preferred stock. BioMedInvest AG, Entrepreneurs Fund, and Capricorn Health-tech Fund co-led the round (and each add a board member) and were joined by returning investors NeoMed (NovaShunt’s largest shareholder) and VI Partners.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in CHF23.7mm for NovaShunt AG
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice